Trials / Not Yet Recruiting
Not Yet RecruitingNCT07269717
A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial on the Efficacy and Safety of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and tolerability of HRS-1893 in subjects with heart failure with preserved ejection fraction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-1893 Tablet | HRS-1893 tablet. |
| DRUG | HRS-1893 Tablet Placebo | HRS-1893 tablet placebo. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2027-03-01
- Completion
- 2027-05-01
- First posted
- 2025-12-08
- Last updated
- 2025-12-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07269717. Inclusion in this directory is not an endorsement.